Information Provided By:
Fly News Breaks for April 16, 2015
QURE, BMY, GNVC, AGTC
Apr 16, 2015 | 08:59 EDT
Roth Capital says gene therapy is the focus of major attention this month because of the recently announced deal between Bristol Myers Squibb (BMY) and UniQure (QURE), and upcoming topline data from Celladon's (CLDN) Phase II CUPID2 study in heart failure. The firm says that Applied Genetic Technologies (AGTC) and GenVec (GNVC) could benefit from the space's increased visibility. It keeps Buy ratings on both names.